Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States | Clinical Pharmacy and Pharmacology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States

Educational Objective
To understand how COVID-19 has affected prescription fill patterns for commonly used drugs
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Haider J. Warraich, MD, VA Boston Healthcare System, 1400 VFW Pkwy, 4B-132, Boston, MA 02132 (hwarraich@partners.org).

Accepted for Publication: May 13, 2020.

Published Online: May 28, 2020. doi:10.1001/jama.2020.9184

Author Contributions: Drs Vaduganathan and Warraich had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Vaduganathan, van Meijgaard, Warraich.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Vaduganathan, Mehra, Warraich.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Vaduganathan, van Meijgaard, Warraich.

Administrative, technical, or material support: van Meijgaard, Warraich.

Supervision: van Meijgaard, Warraich.

Conflict of Interest Disclosures: Dr Vaduganathan reported being supported by the KL2/Catalyst Medical Research Investigator Training award (National Institutes of Health/National Center for Advancing Translational Sciences Award UL 1TR002541); serving on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa; and participating on clinical end point committees for studies sponsored by Novartis and the National Institutes of Health. Dr van Meijgaard is an employee of GoodRx. Dr Mehra reported receiving travel support and consulting fees, paid to Brigham and Women’s Hospital, from Abbott; fees for serving on a steering committee from Medtronic and Janssen (Johnson & Johnson); fees for serving on a data and safety monitoring board from Mesoblast; consulting fees from Portola, Bayer, and Triple Gene; and fees for serving as a scientific board member from NuPulseCV, Leviticus, and FineHeart. Dr Mehra also reported receiving personal fees from Baim Institute for Clinical Research and Roivant. Dr Joseph reported receiving grants from Novartis, Amgen, Otsuka, and Kowa and is a consultant for Novartis. No other disclosures were reported.

Additional Contributions: We acknowledge Diane Li, BA, and Amanda Nguyen, PhD, employees of GoodRx, who assisted with curation and analysis of the data. They did not receive additional financial compensation for these contributions.

Disclaimer: These analyses are based on a representative sample of US pharmacy claims and not based on GoodRx transactions.

References
1.
Vaduganathan  M , Vardeny  O , Michel  T , McMurray  JJV , Pfeffer  MA , Solomon  SD .  Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19.   N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760PubMedGoogle ScholarCrossref
2.
van Meijgaard  J , Li  D , Marsh  T , Nguyen  A . GoodRx research data description. Published April 2020. Accessed April 26, 2020. https://www.goodrx.com/blog/wp-content/uploads/2020/04/GoodRx-Research-Data-Description.pdf
3.
Gautret  P , Lagier  JC , Parola  P ,  et al.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.   Int J Antimicrob Agents. Published online March 20, 2020. doi:10.1016/j.ijantimicag.2020.105949PubMedGoogle Scholar
4.
Liu  M , Caputi  TL , Dredze  M , Kesselheim  AS , Ayers  JW .  Internet searches for unproven COVID-19 therapies in the United States.   JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.1764PubMedGoogle Scholar
5.
Food and Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA. Published March 31, 2020. Accessed May 11, 2020. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Hydroxychloroquine%20Sulfate%20Tablets&st=c
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close